Here the top health news for the day :
Lady hardinge medical college to introduce new DNB and FNB courses soon
Bringing good news to the postgraduate medical aspirants, new DNB and FNB courses are going to commence at Lady Hardinge Medical College (LHMC).
Confirming this, the Director of the institute Subhas Giri informed that the institute aims to start DNB course in emergency medicine and FNB course in reproductive and foetal medicine.
For more information click on the link below:
Johnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test.
This FDA action converts the May 2021 accelerated approval of RYBREVANT to a full approval based on the confirmatory Phase 3 PAPILLON study.
For more information click on the link below:
Government committee to review doctors’ private practice and health sector reforms in J&K
The Jammu and Kashmir administration has established a high-level advisory committee to address private practice by government doctors and propose healthcare reforms. Led by Dr. Ajit Nagpal, the committee includes experts like Dr. Atul Kotwal and Dr. Yashpal. Its key objective is to regulate private practice while optimizing service conditions for doctors. This practice has sparked debate, with concerns about its impact on healthcare quality.
Drawing from global best practices, the committee aims to provide tailored recommendations for Jammu and Kashmir. These efforts seek to enhance healthcare accessibility, affordability, and quality across the region.
For more information click on the link below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.